NCT02254122已完成1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses (20 µg, 50 µg, 100 µg, 200 µg and 400 µg) of BEA 2180 BR for 21 Days in Healthy Male Volunteers (Double-blind, Randomised, Placebo Controlled [at Each Dose Level] Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 59
- 主要终点
- Number of subjects with abnormal findings in physical examination
研究概览
简要总结
Study to investigate safety and tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of BEA 2180 BR
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 30 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy males according to the following criteria (examined at the Screening Visit):
- •Based upon a complete medical history, including the physical examination, vital signs (BP, PR), 12-lead ECG, clinical laboratory tests
- •1.1 No finding deviating from normal and of clinical relevance
- •1.2 No evidence of a clinically relevant concomitant disease
- •Age ≥30 and ≤55 years
- •BMI ≥18.5 and BMI < 30 kg/m2 (Body Mass Index)
- •Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation
排除标准
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, or hormonal disorders
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the Investigator
- •Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- •Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
- •Participation in another trial with an investigational drug within two months prior to administration or during the trial
- •Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
- •Inability to refrain from smoking during the trial
- •Alcohol abuse (more than 60 g/day)
- •Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
- •Excessive physical activities (within one week prior to administration or during the trial)
- •Any laboratory value outside the reference range if indicative of underlying disease or poor health
- •Exclusion criteria specific for this study:
- •Asthma or chronic obstructive pulmonary disease
- •Urinary tract obstruction
- •Occupational (professional) exposure to antimuscarinic substances
研究组 & 干预措施
BEA 2180 BR
Experimental
干预措施: BEA 2180 BR (Drug)
BEA 2180 BR
Experimental
干预措施: Respimat® (Device)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
Placebo
Placebo Comparator
干预措施: Respimat® (Device)
结局指标
主要结局
Number of subjects with abnormal findings in physical examination
时间窗: up to day 42
Number of subjects with clinically significant changes in vital signs
时间窗: up to day 42
Number of subjects with clinically significant changes in 12-lead electrocardiogram
时间窗: up to day 42
Number of subjects with clinically significant changes in laboratory parameters
时间窗: up to day 42
Changes in effective airway resistance (Reff)
时间窗: up to day 25
Body plethysmography
Changes in specific effective airway conductance (SGeff)
时间窗: up to day 25
Body plethysmography
Changes in salivary secretion
时间窗: up to day 21
Number of subjects with adverse events
时间窗: up to day 42
Assessment of tolerability by the Investigator on a 4-point rating scale
时间窗: day 42
次要结局
- Maximum concentration of the analyte in plasma for several time points(up to day 35)
- Time from dosing to maximum concentration in plasma for several time points(up to day 35)
- Area under the concentration-time curve of the analyte in plasma for several time points(up to day 35)
- Amount of analyte that is eliminated in urine for several time points(up to day 34)
- Fraction of analyte excreted in urine for several time points(up to day 34)
- Renal clearance of the analyte in plasma for several time points(up to day 34)
- Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval(up to day 35)
- Predose concentration of the analyte in plasma at steady state immediately before administration of the next dose(up to day 35)
- Terminal rate constant in plasma at steady state (λz,ss)(up to day 35)
- Terminal half-life of the analyte in plasma at steady state (t1/2,ss)(up to day 35)
- Mean residence time of the analyte in the body after 21 administrations at steady state (MRTih,ss)(up to day 35)
- apparent clearance of the analyte in the plasma after extravascular administration at steady state (CL/F,ss)(up to day 35)
- apparent volume of distribution during the terminal phase λz following an extravascular dose at steady state (Vz/F,ss)(up to day 35)
- Accumulation ratio (RA) of the analyte in plasma after multiple dose administration over a uniform dosing interval τ(up to day 35)
- Peak trough fluctuation (PTF)(up to day 35)
研究者
相似试验
已完成
1 期
Single Rising Dose Study of BI 135585 XX in Health Asian Male Volunteers.HealthyNCT01291732Boehringer Ingelheim48
终止
1 期
A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese ParticipantsHealthy VolunteersNCT06009237AbbVie24
已完成
1 期
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male SubjectsHealthyNCT02263976Boehringer Ingelheim101
终止
1 期
Single Rising Dose Study of BI 201335 ZW in Healthy Male SubjectsHealthyNCT02182271Boehringer Ingelheim8
已完成
1 期
A Study in Healthy Men to Test How the Body Takes up and Tolerates Different Doses of BI 765080HealthyNCT04666922Boehringer Ingelheim48